Business Context and Reporting Period
This Form 8-K is a current report filed by TeraWulf Inc. on April 14, 2026. The filing discloses the pricing of a previously announced public offering of common stock under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing details the terms of a capital raise rather than operational financial performance metrics such as revenue or profit.
- Shares Priced: 47,400,000 shares of Common Stock.
- Offering Price: $19.00 per share.
- Gross Proceeds: Approximately $900 million.
- Offering Size Adjustment: Upsized from an initial target of $800 million.
- Expected Closing Date: April 16, 2026 (subject to customary conditions).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 7,110,000 additional shares.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the execution of a significant equity financing event. The company successfully priced the offering at $19.00 per share, resulting in gross proceeds of approximately $900 million, which represents a $100 million increase over the initially anticipated $800 million offering size.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the pricing of the offering and the expectation of closing on April 16, 2026. It references a press release (Exhibit 99.1) for further details.
Risks and Contingencies: The closing of the transaction is subject to customary closing conditions. The filing includes a standard disclaimer that the information furnished in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the final closing date of the offering (expected April 16, 2026) and confirmation of the $900 million gross proceeds.
- Review the attached press release (Exhibit 99.1) for specific details on the use of proceeds.
- Monitor whether the underwriters exercise the 30-day option to purchase the additional 7,110,000 shares.
- Confirm the impact of the new share issuance on total outstanding shares and potential dilution.